BIOMAT Database Logo BIOMAT Database Logo

Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). 2009

J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Department of Internal Medicine, Medical Clinic C, Ludwigshafen, Germany. J.Teichmann@st.josefskrankenhaus.de

Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients without wasting syndrome, and 20 healthy male controls, in whom we analyzed urine and serum samples for both calciotropic hormones and markers of bone metabolism and of endocrine testicular function. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry both in the lumbar spine and Ward's triangle of the left hip. None of the patients received highly-active-antiretroviral-therapy (HAART). Compared to eugonadal HIV-infected patients, subjects with hypogonadism (n = 32; 40%) showed statistically significant decrease of serum osteocalcin (p < 0.05) and elevated urinary excretion of crosslinks (p < 0.05). However, we found 13 and 15, respectively, patients with osteopenia (t-score -1.0 to -2.5 SD below normal) of the lumbar spine. The dissociation between bone formation and resorption and the reduction of of BMD (p < 0.05) is stronger expressed in patients with hypogonadism. Habitual hypogonadism appears to be of additional relevance for bone metabolism of male HIV-positive patients prior to HAART.

UI MeSH Term Description Entries
D007006 Hypogonadism Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism). Hypergonadotropic Hypogonadism,Hypogonadism, Isolated Hypogonadotropic,Hypogonadotropic Hypogonadism,Hypogonadism, Hypergonadotropic,Hypogonadism, Hypogonadotropic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D001851 Bone Diseases, Metabolic Diseases that affect the METABOLIC PROCESSES of BONE TISSUE. Low Bone Density,Low Bone Mineral Density,Osteopenia,Metabolic Bone Diseases,Bone Density, Low,Bone Disease, Metabolic,Low Bone Densities,Metabolic Bone Disease,Osteopenias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015519 Bone Density The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral

Related Publications

J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
May 2012, Clinical endocrinology,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
[The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
August 2010, Zhonghua nei ke za zhi,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
April 2007, The Journal of clinical endocrinology and metabolism,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.
August 2006, Clinical endocrinology,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy.
January 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.
March 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).
July 2015, Journal of clinical and diagnostic research : JCDR,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
[Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy].
March 2004, Anales de pediatria (Barcelona, Spain : 2003),
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy.
September 2002, Metabolism: clinical and experimental,
J Teichmann, and U Lange, and T Discher, and J Lohmeyer, and H Stracke, and R G Bretzel
Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus.
December 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!